Advanced search

News (31)

Hutchmed China to shift strategy toward advanced assets in pipeline	22-11-15	AN
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals	22-11-14	GL
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals	22-11-14	AQ
Transcript : HUTCHMED Limited - Special Call	22-09-12
HUTCHMED China : Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer - Form 6-K	22-08-08	PU
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer	22-08-07	GL
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer	22-08-07	AQ
Transcript : HUTCHMED Limited, H1 2022 Earnings Call, Aug 01, 2022	22-08-01
Transcript : HUTCHMED Limited - Special Call	22-05-02
HUTCHMED China : INSIDE INFORMATION - Form 6-K	22-05-02	PU
HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors	22-05-02	GL
Transcript : HUTCHMED Limited, 2021 Earnings Call, Mar 03, 2022	22-03-03
Olympics-China reports 34 new COVID-19 cases among Games-related personnel	22-01-30	RE
HUTCHMED China : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer - Form 6-K	21-12-06	PU
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer	21-12-05	AQ
Transcript : HUTCHMED Limited, Q2 2021 Earnings Call, Jul 28, 2021	21-07-28
HUTCHMED China : Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval (Form 6-K)	21-07-16	PU
HUTCHMED China : Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency	21-07-15	AQ
HUTCHMED China : U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors (Form 6-K)	21-07-02	PU
U.S. FDA Accepts Filing of HUTCHMED’s NDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors	21-07-01	GL
Transcript : HUTCHMED Limited - Special Call	21-05-27
Transcript : HUTCHMED Limited - Special Call	21-05-26
Hutchison China MediTech : HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors	21-05-03	AQ
Transcript : Hutchison China MediTech Limited, 2020 Earnings Call, Mar 04, 2021	21-03-04
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors	20-12-28	GL
Transcript : Hutchison China MediTech Limited - Special Call	20-06-01
Eli Lilly and : Hutchison China MediTech Limited - Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab	20-05-27	AQ
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab	20-05-26	GL
Transcript : Hutchison China MediTech Limited, 2019 Earnings Call, Mar 03, 2020	20-03-03
Transcript : Hutchison China MediTech Limited - Special Call	19-09-30
Transcript : Hutchison China MediTech Limited, 2018 Earnings Call, Mar 11, 2019	19-03-11

Insiders

Marek Kania

Presently, Marek Kania occupies the position of Chief Medical Officer & Managing Director at Hutchison China MediTech Ltd. Dr. Kania is also Member of American Society of Clinical Oncology and Member of American Association for Cancer Research. Dr. Kania received an MBA from The University of Chicago Booth School of Business.

Marek Kaniak

Marek Kaniak currently works at Famur Famak SA, as Member-Supervisory Board.

Henryk Marek Kania

Henryk Marek Kania founded Zaklady Miesne Henryk Kania SA in 1990, where he is working as Member-Supervisory Board.
Mr. Kania also formerly worked at NWAI Dom Maklerski SA, as Member-Supervisory Board.

Nia Kania is currently working as the Director-Finance & Risk Management at PT Bank Pembangunan Daerah Jawa Barat dan Banten Tbk.
She completed her undergraduate degree at Universitas Padjadjaran in 1990 and her graduate degree in 2020.

Jan Kania

Regina Kania

Karol Kania

No results for this search